Medizinportal Arztsuche Apothekensuche KliniksucheHealth Provider Directory - Health in Germany - english-language-version
Home DocSearch ClinicSearch HealthSites


Leading Colorectal Patient Organisation Calls on EU Countries to Improve Poor Standards of Care
Barcelona, Spain ( PRN/ots ) - europacolon has called on all governments to implement existing EU recommendations on colorectal cancer screening following a new report published today that shows the disease to be significantly neglected despite being the second most common cancer in Europe.( 1 ) Welcoming the (...)
Xeloda Meets Primary Endpoint in Multinational Phase III Advanced Colorectal Cancer Study
Basel, Switzerland ( PRN/ots ) - - Roche to Approach World - Wide Regulatory Authorities for a New File Submission Roche announced today that a large, international Phase III study ( NO16967 ) of 627 previously treated patients with advanced colorectal cancer met its primary endpoint of progression - (...)
Jane Seymour Lends Support to Recognise the Hopes and Achievements of People Living With Rheumatoid Arthritis ( RA )
Maidenhead, England ( PRN/ots ) - - 26 Men and Women With RA From Across Europe Honoured as They Share Their Inspirational Stories Actress, artist and activist Jane Seymour will host the first My Day for RA European event in Barcelona, Spain this evening (...)
Boehringer Ingelheim Initiates SPRING Study of Aptivus( R ) ( tipranavir ) in Diverse Group of Highly Treatment - Experienced HIV - Positive Patients
Ingelheim, Germany ( PRN/ots ) - Boehringer Ingelheim GmbH announced today that it has begun to enroll patients in the SPRING study. The SPRING study will be one of the largest racially and gender diverse international studies of highly treatment - experienced HIV - 1 infected (...)
Take a Peek at the Undercover World of Parasites
Monheim, Germany, May 25, 2010 ( PRN/ots ) - Who said that learning about bugs was boring? An amazing new journey through the wonderful world of parasites launches on YouTube today. Four exciting videos, inspired by the 'Parasites Life Undercover' exhibition at the Berlin Natural History (...)
Recruitment Ongoing in Europe for Two Tibotec Phase III Clinical Trials Studying TMC278 in Treatment - Naïve HIV - Infected Adults
Cork, Ireland ( PRN/ots ) - - Once - Daily TMC278 is the Third Anti - HIV Compound to be Developed in Tibotec Virology Portfolio Tibotec Pharmaceuticals is currently recruiting HIV - positive, treatment - naïve adults ( or those who have never taken antiretroviral medication before ) in Europe for (...)
Levact( R ) ( bendamustine ) Recommended for Approval in Europe for Treating Blood Cancers
Cambridge, England, March 19, 2010 ( PRN/ots ) - Mundipharma announced today that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has issued a positive opinion recommending that marketing authorisations can be granted in Germany and the following Member (...)
New Study Shows ENBREL( R ) ( etanercept ) Is More Effective than a DMARD in the Treatment of Symptoms of Ankylosing Spondylitis Patients
Maidenhead, England ( PRN/ots ) - - Data From Another Study Supported the use of ENBREL for up to Five Years in Ankylosing Spondylitis Patients New safety and efficacy data for active ankylosing spondylitis ( AS ) patients treated with ENBREL( R ) ( etanercept ) were presented at the American (...)
Pieris strengthens its management, as it prepares for the clinical development of PRS - 050, an Anticalin® - based novel cancer therapy
Freising - Weihenstephan ( na Originaltextservice ) - Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced the appointment of Dr Angelika Stern as Chief Operating Officer to the Company. Pieris has also announced the promotion with (...)
Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
Paris ( PRN/ots ) - Sanofi - aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis ( RMS ). In this study, both doses of teriflunomide ( 7 and 14mg ) significantly (...)
Soaring Cholesterol Levels Could Plunge Europe Into a Welfare Crisis by 2020 if not Tackled Today
Brussels ( PRN/ots ) - - Stockholm Network Report Says Crisis can be Averted by Better Practice Patterns and Newer Therapies A major new report by think tank, The Stockholm Network, shows policy makers are not doing enough to tackle rising cholesterol levels. The report (...)
Invitation to the International Press Conference of the 11th Congress of the European Hematology Association
Rotterdam, Netherlands ( PRN/ots ) - - RAI CONVENTION CENTRE, AMSTERDAM Presentation of results of groundbreaking hematological research in the fields of donor stem - cell transplantation and thrombosis The 11th Congress of the European Hematology Association ( EHA ) is being held from June 15 to (...)
Researchers Confirm Omega - 3 EPA Required for Antidepressant Benefits
Dartmouth, Canada ( PRN/ots ) - Researchers at the University of Illinois at Chicago completed a review of previously published research on antidepressant benefits of Omega - 3 essential fatty acids eicosapentaenoic acid ( EPA ) and docosahexaenoic acid ( DHA ). The review comprised a meta - analysis of 15 randomized, double - (...)
AstraZeneca to Start Phase III Trials With ZACTIMA ( TM ) ( ZD6474 ) - a Novel Targeted Lung Cancer Treatment
Barcelona, Spain ( PRN/ots ) - AstraZeneca ( LSE: AZN, NYSE: AZN ) announced today that it is to progress to Phase III studies with its novel oncology compound ZD6474 - now also known by its trade name, ZACTIMA ( TM ). Recruitment to Phase III studies evaluating the anti - (...)
Takeda Responds to FDA Advisory Committee Recommendation
London, July 15, 2010 ( PRN/ots ) - The U.S. Food and Drug Administration ( FDA ) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular ( CV ) safety of rosiglitazone, as presented (...)
Zeltia Raises EUR 65 Million Through Institutional Placing
Madrid ( PRN/ots ) - Zeltia S.A.( ZEL SM; ZEL.MC ), the Spanish biotechnology company, today announces that it has raised Eur 65 million of new funds through a private placement of 10.75 million new ordinary shares with qualified institutional investors at a price of Eur 6.05 per (...)
T - Cell Lymphoma Patients Achieve Long Lasting Responses With Genmab's HuMax - CD4
Copenhagen, Denmark ( PRN/ots ) - Genmab A/S ( CSE: GEN ) announced today that cutaneous T - cell lymphoma ( CTCL ) patients in the HuMax - CD4 Phase II studies achieved long lasting responses, with an average response duration of more than 6.6 months. This duration of response data (...) Conference Call Genmab will hold a conference call to discuss the news today Wednesday, September 1, 2004 at: 3:30 pm CET 2:30 pm BST 9:30 am EDT The conference call will be held in English. The dial in numbers are as follows: +1 - 800 - 500 - 0177 ( in the US ) and ask for the Genmab conference call +1 - 719 - 457 - 2679 ( outside the US ) and ask for the Genmab conference call About Genmab A/S Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life - threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb( TM ) platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab is headquartered in Copenhagen, Denmark, and has operations in Utrecht, The Netherlands, and Princeton, New Jersey in the US. For more information about Genmab, visit . Except for the historical information presented herein, matters discussed in this press release are forward looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements, e.g. unforeseen exchange rate and interest rate fluctuations, delayed or unsuccessful development projects. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes"; "anticipates"; "plans"; "expects"; "estimates"; or similar statements are forward - looking statements. Genmab is not under an obligation to up - date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law. HuMax - CD4( TM ) is a trademark of Genmab A/S. UltiMAb( TM ) is a trademark of Medarex, Inc. Web site: ots Originaltext: Genmab A/S Im Internet recherchierbar: Contact: Rachel Gravesen, VP IR&PR of Genmab A/S, +45 - 33 - 44 - 77 - 34, or mobile, +45 - 25 - 40 - 30 - 01,
Roche Requests Re - Examination of CHMP Opinion on Tarceva in Pancreatic Cancer at the European Medicines Agency
Basel, Switzerland ( PRN/ots ) - - First Treatment for Years to Have Shown a Significant Survival Benefit for Patients Roche announced today that it has requested a re - examination of the data supporting the filing of their breakthrough cancer medicine, Tarceva, for the treatment (...)
Bridging Science and Art / Electroacoustic prelude to the informal EU Council meeting in Graz
Graz ( na Originaltextservice ) - - Cross reference: Picture is available free of charge at - "Poèmes Electroniques" on April 20 in Graz range from the sensorial experience of three - dimensional acoustics to the sound of a diesel engine (...)
Vectibix( R ) in Combination With Chemotherapy Significantly Improves Progression - Free Survival in First - Line Metastatic Colorectal Cancer
Thousand Oaks, California ( PRN/ots ) - Amgen ( Nasdaq: AMGN ) today announced detailed results from the Phase 3 '203' trial evaluating Vectibix( R ) ( panitumumab ) administered in combination with FOLFOX ( an oxaliplatin - based chemotherapy ) as the first - line treatment of metastatic colorectal cancer ( mCRC ). In this trial, (...)
Occlutech Receives Positive Ruling in German Proceeding Initiated by AGA Medical
Jena, Germany ( PRN/ots ) - Occlutech GmbH, the leading European developer of products for septal closure, today announced that the district court of Frankfurt, Germany reversed an earlier court injunction obtained by AGA Medical against Occlutech's sales and marketing activities relating to the newly launched (...)
Tarceva Receives Positive Opinion in Europe for Maintenance Treatment of Advanced Lung Cancer
Basel, Switzerland, March 19, 2010 ( PRN/ots ) - Roche ( SIX: RO, ROG; OTCQX: RHHBY ) today announced that the European Committee for Medicinal Products for Human Use ( CHMP ) has issued a positive opinion for use of Tarceva( R ) ( erlotinib ) as a maintenance therapy for people with advanced (...)
Herceptin Eradicates Tumours and may Reduce the Need for Mastectomies in Women With Inflammatory HER2 - Positive Breast Cancer - one of the Most Aggressive and Fastest Growing Forms of the Disease
Barcelona, Spain ( PRN/ots ) - - Abstract no: 2030, Being Presented at ECCO in the "Proffered Papers: Breast Cancer - Early Disease" Session in the Forum, Starting at 09.00am on Wednesday 26th September 2007 - For non - US Media Only New data show that the (...)
White biotechnology / German industry collaborating closely on microbial genome research
Dusseldorf ( na Originaltextservice ) - Prominent companies in the chemicals, pharmaceuticals and nutrition industries have come together for the first time under the umbrella of the "Industrieverbund Mikrobielle Genomforschung” ( industry/science association to promote microbial genome research ), Dusseldorf, with the aim of advancing microbial genome research as a (...)
Xenomics Announces Development of a New Method for Isolation of Cell - Free Nucleic Acids From Urine
New York ( PRN/ots ) - - Prototype Research Kits Approach Commercialization Phase and Target the Growing Field of Genomic - Based Molecular Diagnostics Xenomics, Inc. ( OTC Bulletin Board: XNOM; FWB:XE7 ), the source of next - generation medical DNA diagnostic tests, today announced that it has (...)
Avastin( R ) Significantly Prolongs Progression Free Survival in Patients With Advanced Lung Cancer
Chicago, Illinois ( PRN/ots ) - - Only First - line Treatment to Demonstrate Extended Survival in Over a Decade Avastin ( bevacizumab ), significantly improves the time patients with advanced non - small cell lung cancer ( NSCLC ) live without their disease advancing ( "progression free survival" ) when added to cisplatin/ (...)
Simplify pain management by calculating the Medication Quantification Scale ( MQS ) online / The P.A.I.N. Initiative presents the first web - based tool for the quantification of pain medication
Aachen ( na Originaltextservice ) - With the Medication Quantification Scale ( MQS ) Online Calculator, the P.A.I.N. ( Pain Associates' International Network ) Initiative by the German pharmaceutical company Grunenthal GmbH offers a web - based tool for the quantification of medication used in pain populations. The MQS (...)
New Study Suggests Combining Breakthrough Therapies Tarceva( R ) and Avastin( R ) May Provide More Hope for Lung Cancer Patients
Basel, Switzerland ( PRN/ots ) - A new study( 1 ) suggests that treatment with the combination of the innovative cancer drugs Avastin ( bevacizumab ) and Tarceva ( erlotinib ) or Avastin with chemotherapy, improves progression - free survival in patients with recurrent or refractory non - small cell lung cancer ( NSCLC ), the (...)
Amgen Statement on CHMP Opinion on Vectibix( R ) ( Panitumumab ) Use With Chemotherapy in Metastatic Colorectal Cancer
Thousand Oaks, California ( PRN/ots ) - Amgen today issued the following statement: Amgen has received notice that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a negative opinion for Amgen's application to extend the marketing (...)
BIO 2010: German Molecular Diagnostics Segment Posting Double - Digit Growth
Berlin/Chicago ( na Originaltextservice ) - Molecular diagnostics has quickly become one of the most important biotechnology segments in Germany. With an estimated 10 percent share of the EUR 2 billion German diagnostics market, the segment enjoys a compound annual growth rate of (...)
Disaster Victim Identification Process Update
Phuket, Thailand ( PRN/ots ) - The Thai government is in the process of establishing an international standard post mortem and ante - mortem identification centre in Phuket as the processing of victims of the tsunami that hit Thailand gets underway. There are now disaster victim (...)
RVX - 208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease
Calgary, Canada, November 10 ( PRN/ots ) - - First in Class Drug Illustrates Early Signal of Transport of Key Amyloid Marker From Brain - TSX Exchange Symbol: RVX Resverlogix Corp. ( "Resverlogix" ) ( TSX:RVX ) announced today that treatment with its lead drug RVX - 208, a (...)
New ASCO Recommendation for Postmenopausal Women With Early Breast Cancer
London, November 15 ( PRN/ots ) - - Optimal Adjuvant Therapy Should Now Include an AI Such as 'Arimidex' ( anastrozole ) in Order to Reduce the Risk of Tumour Recurrence Today, the American Society of Clinical Oncology ( ASCO ) Technology Assessment Panel announced a fundamental change to (...)
The Future of Urology in Question: New Survey Reveals the Top Concerns Facing Specialists Today
London and Staines, England ( PRN/ots ) - New research by Astellas Pharma Europe Ltd. today reveals the top three challenges facing urologists across Europe are a lack of funding for research and development; a lack of understanding amongst referrers; and a lack of new treatments (...)
Europe Steps Up Biodiesel Use / Degussa catalyst enables commercial manufacture
Dusseldorf ( na Originaltextservice ) - - Cross - reference: photo is available at - Biodiesel is becoming increasingly popular as an alternative to the traditional mineral oil - based fuel and that applies throughout Europe.Although Germany is clearly the biggest (...)
Once Monthly C.E.R.A. Could Save About 50 Prozent of the Time Health Professionals Spend on Anaemia Management in Dialysis Centres Each Year
Basel, Switzerland ( PRN/ots ) - - New Study Reveals Potential for Improved use of Resources Whilst Maintaining High Quality Anaemia Management A new study has found that converting dialysis patients from more frequently administered erythropoiesis - stimulating agents ( ESAs ) to once - monthly C.E.R.A., a continuous (...)
New Research Shows ACTOS( R ) ( pioglitazone HCI ) is Associated With a 38 Prozent Lower Risk of Heart Attack in Type 2 Diabetes
Amsterdam ( PRN/ots ) - - For Non - US Media Only New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes ( EASD ), further support the cardiovascular safety of ACTOS( R ) ( pioglitazone HCI ) and its (...)
INTERCEPT Blood System Received TÜV Approval for Storage of Platelets up to 7 Days
Munich, Germany ( PRN/ots ) - - Longer Storage Period Makes Platelets More Readily Available to European Transfusion Blood Centers European subsidiaries of Baxter International Inc. ( NYSE: BAX ) and Cerus Corporation ( NASDAQ: CERS ) today announced that they have received CE Mark Certification from TÜV Product (...)
The Disease Modifying Effect of Chondroitin Sulphate in Patients With Knee Osteoarthritis has Been Confirmed by MRI
Barcelona ( PRN/ots ) - A group of Canadian researchers led by Prof. Jean - Pierre Pelletier, Head of the Osteoarthritis Research Unit, at the University of Montreal Hospital Research Centre, published a clinical trial, in which they confirm, for the first time using quantitative Magnetic Resonance (...)
Danish Court Issues Preliminary Injunction That Prohibits Sale of Generic Lipitor Product
New York ( PRN/ots ) - Pfizer Inc said today that a Danish court has granted a preliminary injunction against Nomeco A/S - - the largest pharmaceutical wholesaler in Denmark - - that prohibits the sale of a generic version of Lipitor by generics manufacturer Ranbaxy. The injunction, (...)
Macrochem Acquires Option To License Pexiganan, a Novel Topical Anti - Infective for Treatment of Diabetic Foot Infection, from Genaera
Wellesley Hills, Massachusetts ( PRN/ots ) - - Broadens late - stage product development portfolio building on lead product candidate EcoNail in Phase 2 trial for onychomycosis MacroChem Corporation ( OTCBB: MACM ) today announced that it has signed an exclusive option to acquire exclusive worldwide license rights (...)
More Choice for More Women
San Antonio, Texas ( PRN/ots ) - - 'The Latest Hormonal Treatment Options in the Breast Cancer Continuum' - An AstraZeneca Sponsored Webcast From the 2004 San Antonio Breast Cancer Symposium This webcast will announce key new data for 'FASLODEX' and 'ARIMIDEX' that is being presented (...)
JEWEL Programme Results Show That a New Therapy, Caduet( R ), can Optimise Treatment for Patients With Hypertension and Additional Cardiovascular ( CV ) Risk Factors
Madrid, Spain ( PRN/ots ) - - Caduet, Single - Pill Amlodipine and Atorvastatin Combination, Helps Patients Reduce Calculated Risk for a Fatal CV Event by 29 to 52 Percent Results from the JEWEL programme show that single - pill amlodipine/atorvastatin therapy, also known as Caduet, (...)
Isotechnika's Independent Data Monitoring Committee Conducts Review of Phase 2b Kidney Transplant Trial
Edmonton ( PRN/ots ) - - Company Set to Host Evening Symposium at ATC Isotechnika Inc. announced today that an independent data monitoring committee ( DMC ) has met and reviewed the interim data from the Phase 2b kidney transplant ( PROMISE ) trial. The review included 3 month (...)
Isotechnika's Partner, Lux Biosciences, Receives Orphan Drug Designation for Ophthalmic Indications of ISA247
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. ( TSX: ISA ) announced today that its partner, Lux Biosciences, has been granted orphan drug designation from the U.S. Food and Drug Administration ( FDA ) for ISA247, referred to as LX211 by Lux, for the treatment of non - infectious posterior, (...)
Efficacy of Boehringer Ingelheim's Pramipexole ( Mirapexin( R )/Sifrol( R ) Also Demonstrated in Patients With Daytime RLS Symptoms
Ingelheim Am Rhein, Germany ( PRN/ots ) - - Studies Reinforce the Benefits of Pramipexole From Daytime Symptom Control, Including Afternoon and Early Evening Onset - For Healthcare Media Outside the U.S.A. New data demonstrate that pramipexole ( Mirapexin( R )/Sifrol( R ) ) is also efficacious and well - tolerated (...)
New Data Show Duloxetine Maintained Pain Reduction for More Than Six Months in Patients With Diabetic Peripheral Neuropathic Pain
Indianapolis ( PRN/ots ) - - Study with duloxetine evaluating long - term pain reduction in treatment of DPNP is first to exceed three months Duloxetine hydrochloride maintained pain reduction in the treatment of diabetic peripheral neuropathic pain ( DPNP ) for more than six months,( 1 ) according to (...)
Cordis Corporation to Appeal Court Ruling
Miami ( PRN/ots ) - Cordis Corporation, a Johnson & Johnson company, today received a ruling from a court in the Netherlands that found the company infringed a Boston Scientific patent related to a catheter shaft that is used in the delivery system for the (...)
New Data Highlight Increased EGFR Gene Copy Number as the Most Positive Biomarker in Determining Which Patients are Most Likely to Benefit From gefitinib ( Iressa( TM ) )
Macclesfield, England, November 15 ( PRN/ots ) - - For Health Professional Press Only - For International Journalists Only - Not for US Media - Retrospective ISEL Study Analysis Identifies Potential Indicator of Response to Treatment With gefitinib in Advanced NSCLC patients Data presented today at (...)

back... 1 2 3 4 5 6 7 8 9 10 11 more...

» German Health-Sites

Medical and health related Websites from Germany

Alternative Medicine
Beauty and Wellness
Manufacturers of Medical Equipment
German Doctors Worldwide
German Medicine and Patient Transfer
Special Diagnoses
Nutrition and Diet
Fitness and Sports
Womens Health
Health Insurance
Other Insurances
Literature and Publishers
Newspaper / Magazines
Portals and Directories
Portals and Directories Dental Medicine
Public Health
Governmental Links
North Rhine-Westphalia
Travel Medicine
Medical malpractice
Visually Impaired
Seniors / 50+
Seniors / Living
Medical Technology
Children-, Youth- and Social Work

© 2003-2008 Health Provider Directory
Clinics and Physicians
Berlin, Germany Dienstag, 28.9.2021.
Sitemap (Sitemap German) Imprint Press (German)
Ärzteverzeichnis Klinikverzeichnis Apothekenverzeichnis Ärztesuche
 Mon, 27 Sep 2021 12:17:23 GMT
Werben im Gesundheitssektor / Medizin

Health Provider Directory

Medizin und Gesundheit - Arztsuche Kliniksuche Apothekensuche